Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Gastrointestinal 6Other hematologic neoplasm 5Other 5Gynecologic 5Genitourinary 4Other solid neoplasm 3Lymphoid 3Head & Neck 3Thoracic 2Tumor-Agnostic 1Other neoplasm 1Endocrine 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 56Specimen Handling 28Biopsy 27Magnetic Resonance Spectroscopy 26Paclitaxel 22Blood Specimen Collection 21Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8Taxes 8Ipilimumab 8durvalumab 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Counseling × Tumor-Agnostic × 1 year × Clear all
NCT05847686 2025-11-05

Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer

University of Washington

Phase 1/2 Completed
55 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡